SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending after delivering a double beat on earnings with solid guidance, reinforcing its position as a cybersecurity leader amidst increasing global cyber threats. The community is actively discussing whether AI is a tailwind or a threat to the sector, with many viewing recent dips as a buying opportunity given the crucial and growing demand for advanced security solutions.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is witnessing an intense community debate following an unexpected sharp sell-off, despite surging crude oil prices and geopolitical tensions propelling other energy stocks higher. Many investors are questioning if the downturn is due to corporate dilution or market manipulation, drawing parallels to its history of extreme volatility.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending following its latest earnings report, which showed a beat on EPS and revenue but was met with mixed community reactions due to conservative guidance. The conversation is highly polarized, with ongoing debate on how AI impacts its core DevSecOps platform, alongside persistent and active discussion of potential acquisition rumors, notably from Datadog.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant bullish momentum driven by an EU regulatory recommendation for its combined COVID-19/flu vaccine, the FDA's decision to review its standalone flu shot, and positive long-term data from its personalized cancer vaccine collaboration with Merck. These developments are fueling strong community discussions around potential short squeezes and the company's expanding mRNA pipeline beyond COVID-19, including its integration of AI for drug discovery.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is trending following its strategic acquisition of Covelya Group, a "company-maker" deal that significantly expands its subsea technology offerings and market reach as a global prime contractor. The community is discussing the long-term bullish implications of this vertical integration and significant battery orders, alongside short-term concerns regarding share dilution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is a major talking point as investors eagerly await its business update call, expecting Dr. PSS to reveal breakthroughs in Anktiva's global strategy and the BioShield platform, while simultaneously navigating intense community chatter around perceived short interest manipulation.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing a notable surge, driven by strong community engagement and cultural anticipation surrounding the upcoming 4/20 cannabis observance. The crypto, operating on Solana, is gaining traction as users highlight its outperformance against traditional cannabis stocks and its connection to the broader cannabis movement.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is a major talking point following its Q4 earnings report and a significant AI data center deal with Google and Anthropic, which underscore its strategic pivot from pure Bitcoin mining to high-performance computing infrastructure. The community is sharply divided between those who view its performance as "manipulation" and those who see "monster" potential in its AI-driven growth and strong relative strength compared to other crypto-exposed names.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending following a strong quarterly earnings beat and robust 2026 outlook, which confirmed its profitability and growing cash position. The community is buzzing about the company's compelling valuation, high short interest, and the increasing speculation around a potential share buyback or acquisition, fueled by its expanding product portfolio and key Eli Lilly partnership.

Ross Stores, Inc. engages in the operation of off-price retail apparel and home accessories stores. Its products include branded and designer apparel, accessories, footwear, and home fashions through the Dress for Less and dd's DISCOUNTS brands. The company was founded by Stuart G. Moldaw in 1957 and is headquartered in Dublin, CA.

Ross Stores, Inc.

Ross Stores is trending due to its recent strong earnings report, with the community widely celebrating impressive financial results and robust sales growth. This performance, coupled with increased dividends and a new stock repurchase authorization, highlights continued strength in the off-price retail sector as consumers seek value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bicycle Therapeutics (NASDAQ:BCYC) Upgraded to "Strong-Buy" at Jefferies Financial Group

Jefferies Financial Group raised shares of Bicycle Therapeutics to a "strong-buy" rating in a research report on Tuesday...

Bicycle Therapeutics (BCYC) Projected to Post Quarterly Earnings on Tuesday

Bicycle Therapeutics (NASDAQ:BCYC) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, MarketBeat...

Principal Financial Group Inc. Grows Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Principal Financial Group Inc. lifted its holdings in shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Free Report) by 64.7% in the 3rd quarter, according to its most recent Form 13F...

Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.6% - Time to Sell?

Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Down 2.6% - Time to Sell...

Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Recommendation of "Hold" from Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) has been given a consensus rating of "Hold" by the thirteen research firms that are presently covering the stock, MarketBeat...

Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

Alethia Young Sells 3,289 Shares of Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CFO Alethia Young sold 3,289 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an...

Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CFO Sells 4,334 Shares of Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CFO Alethia Young sold 4,334 shares of the firm's stock in a transaction dated Monday, January 5th. The shares were sold at an...

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.96	--	--	N/A
Q3 '25	-$1.08	-$0.85	21.13%	BEAT
Q2 '25	-$0.95	-$1.14	-20.49%	MISSED
Q1 '25	-$0.85	-$0.88	-4.09%	MISSED
Q4 '24	-$0.86	-$0.75	12.46%	BEAT

BCYC
Bicycle Therapeutics Plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BCYC News

BCYCBicycle Therapeutics Plc - ADR